Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Sadikovic, Bekim ^a   Thorner, Paul ^a   Chilton MacNeill, Susan ^a   Martin, Jeff W ^c   Cervigne, Nilva K ^b   Squire, Jeremy ^c   Zielenska, Maria ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; CELL CYCLE PROTEIN; CELL DIVISION CYCLE PROTEIN 5; CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DOXORUBICIN; HISTONE H2B; LIMBIC SYSTEM ASSOCIATED MEMBRANE PROTEIN; METHOTREXATE; MYC PROTEIN; OSTEOPONTIN; PROTEIN DOCK5; PROTEIN FOS; PROTEIN HISTH2BE; PROTEIN IBSP; PROTEIN P53; PROTEIN RECQL4; RECQ HELICASE; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; SIALOPROTEIN; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1B; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MESSENGER RNA; RUNX2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; MALE; OSTEOBLAST; OSTEOSARCOMA; QUANTITATIVE ANALYSIS; ADOLESCENT; BIOPSY; BONE TUMOR; CHILD; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT FAILURE; UPREGULATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OSTEOSARCOMA; RETROSPECTIVE STUDIES; RNA, MESSENGER; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77952065237     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-202     Document Type: Article

References (55)

1. Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 2008, 3(3):228-231. 10.2174/157488708785700267, 2778092, 18782081.
2. Gorlick R. Osteosarcoma: clinical practice and the expanding role of biology. Journal of musculoskeletal & neuronal interactions 2002, 2(6):549-551.
3. Batanian JR, Cavalli LR, Aldosari NM, Ma E, Sotelo-Avila C, Ramos MB, Rone JD, Thorpe CM, Haddad BR. Evaluation of paediatric osteosarcomas by classic cytogenetic and CGH analyses. Mol Pathol 2002, 55(6):389-393. 10.1136/mp.55.6.389, 1187277, 12456778.
4. Lim G, Karaskova J, Beheshti B, Vukovic B, Bayani J, Selvarajah S, Watson SK, Lam WL, Zielenska M, Squire JA. An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer 2005, 42(4):392-403. 10.1002/gcc.20157, 15660435.
5. Lim G, Karaskova J, Vukovic B, Bayani J, Beheshti B, Bernardini M, Squire JA, Zielenska M. Combined spectral karyotyping, multicolor banding, and microarray comparative genomic hybridization analysis provides a detailed characterization of complex structural chromosomal rearrangements associated with gene amplification in the osteosarcoma cell line MG-63. Cancer Genet Cytogenet 2004, 153(2):158-164. 10.1016/j.cancergencyto.2004.01.016, 15350306.
6. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003, 145(1):1-30. 10.1016/S0165-4608(03)00105-5, 12885459.
7. Selvarajah S, Yoshimoto M, Maire G, Paderova J, Bayani J, Squire JA, Zielenska M. Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet 2007, 179(1):52-61. 10.1016/j.cancergencyto.2007.08.003, 17981215.
8. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L, Zielenska M. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003, 38(3):215-225. 10.1002/gcc.10273, 14506695.
9. Zielenska M, Marrano P, Thorner P, Pei J, Beheshti B, Ho M, Bayani J, Liu Y, Sun BC, Squire JA, et al. High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenet Genome Res 2004, 107(1-2):77-82. 10.1159/000079574, 15305059.
10. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clinical orthopaedics and related research 2008, 466(9):2114-2130. 10.1007/s11999-008-0335-z, 2492997, 18563507.
11. Thomas D, Kansara M. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem 2006, 98(4):757-769. 10.1002/jcb.20850, 16598744.
12. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, Rodda SJ, Snay E, Dunning P, Fahey FH, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008, 22(12):1662-1676. 10.1101/gad.1656808, 2428063, 18559481.
13. Gokgoz N, Wunder JS, Mousses S, Eskandarian S, Bell RS, Andrulis IL. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 2001, 92(8):2181-2189. 10.1002/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO;2-3, 11596036.
14. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer research 1990, 50(24):7950-7954.
15. Radig K, Schneider-Stock R, Oda Y, Neumann W, Mittler U, Roessner A. Mutation spectrum of p53 gene in highly malignant human osteosarcomas. Gen Diagn Pathol 1996, 142(1):25-32.
16. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clinical orthopaedics and related research 2002, 397:40-52. 10.1097/00003086-200204000-00007, 11953594.
17. Deshpande A, Hinds PW. The retinoblastoma protein in osteoblast differentiation and osteosarcoma. Curr Mol Med 2006, 6(7):809-817.
18. Sadikovic B, Yoshimoto M, Al-Romaih K, Maire G, Zielenska M, Squire JA. In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS ONE 2008, 3(7):e2834. 10.1371/journal.pone.0002834, 2515339, 18698372.
19. Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire JA, Zielenska M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 2009, 18(11):1962-1975. 10.1093/hmg/ddp117, 19286668.
20. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M, Magagnoli G, Balladelli A, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 1998, 55(6):556-563. 10.1159/000011912, 9778623.
21. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, Mercola D. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 1990, 5(7):989-1000.
22. Lu XY, Lu Y, Zhao YJ, Jaeweon K, Kang J, Xiao-Nan L, Ge G, Meyer R, Perlaky L, Hicks J, et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 2008, 6(6):937-946. 10.1158/1541-7786.MCR-07-2115, 2693718, 18567798.
23. Maire G, Yoshimoto M, Chilton-MacNeill S, Thorner PS, Zielenska M, Squire JA. Recurrent RECQL4 imbalance and increased gene expression levels are associated with structural chromosomal instability in sporadic osteosarcoma. Neoplasia 2009, 11(3):260-268. 263p following 268, 2647728, 19242607.
24. Davicioni E, Wai DH, Anderson MJ. Diagnostic and prognostic sarcoma signatures. Molecular Diagnosis and Therapy 2008, 12(6):359-374.
25. Cervigne NK, Reis PP, Machado J, Sadikovic B, Bradley G, Galloni NN, Pintilie M, Jurisica I, Gilbert R, Gullane P, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Human Molecular Genetics 2009,
26. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812. 10.1126/science.1164382, 2820389, 18772396.
27. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis M, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008,
28. Rogers S, Cambrosio A. Making a new technology work: the standardization and regulation of microarrays. Yale Journal of Biology and Medicine 2007, 80(4):165-178. 2347363, 18449388.
29. Farragher SM, Tanney A, Kennedy RD, Paul Harkin D. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochemistry and Cell Biology 2008, 130(3):435-445. 10.1007/s00418-008-0479-7, 18679706.
30. Li G, Zhang W, Zeng H, Chen L, Wang W, Liu J, Zhang Z, Cai Z. An integrative multi-platform analysis for discovering biomarkers of osteosarcoma. BMC Cancer 2009, 9:150. 10.1186/1471-2407-9-150, 2691408, 19445706.
31. Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes, Chromosomes and Cancer 2009, 48(8):679-693.
32. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49(6):1221-1230. 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E, 6174200.
33. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994, 12(12):2699-2705.
34. Fritsch MK, Bridge JA, Schuster AE, Perlman EJ, Argani P. Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue. Pediatr Dev Pathol 2003, 6(1):43-53. 10.1007/s10024-002-0013-1, 12375129.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
36. Bender R, Lange S. Adjusting for multiple testing--when and how?. Journal of clinical epidemiology 2001, 54(4):343-349. 10.1016/S0895-4356(00)00314-0, 11297884.
37. Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 2008, 9(6):394-408. 10.2174/138920208785699580, 2691666, 19506729.
38. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer research 1994, 54(5):1169-1174.
39. Brazier H, Stephens S, Ory S, Fort P, Morrison N, Blangy A. Expression profile of RhoGTPases and RhoGEFs during RANKL-stimulated osteoclastogenesis: identification of essential genes in osteoclasts. J Bone Miner Res 2006, 21(9):1387-1398. 10.1359/jbmr.060613, 16939397.
40. Carlo-Stella C, Lavazza C, Locatelli A, Vigano L, Gianni AM, Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007, 13(8):2313-2317. 10.1158/1078-0432.CCR-06-2774, 17438088.
41. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Critical Reviews in Eukaryotic Gene Expression 2004, 14(1-2):1-41. 10.1615/CritRevEukaryotGeneExpr.v14.i12.10, 15104525.
42. Zhang HY, Jin L, Stilling GA, Ruebel KH, Coonse K, Tanizaki Y, Raz A, Lloyd RV. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine 2009, 35(1):101-111. 10.1007/s12020-008-9129-z, 19020999.
43. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10(2):267-275. 10.1007/s10495-005-0801-y, 15843888.
44. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer research 2001, 61(9):3750-3759.
45. Vladimirova V, Waha A, Luckerath K, Pesheva P, Probstmeier R. Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. Journal of Neuroscience Research 2008, 86(11):2450-2461. 10.1002/jnr.21686, 18438928.
46. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer research 2006, 66(4):2195-2201. 10.1158/0008-5472.CAN-05-3558, 16489021.
47. Pregizer S, Baniwal SK, Yan X, Borok Z, Frenkel B. Progressive recruitment of Runx2 to genomic targets despite decreasing expression during osteoblast differentiation. Journal of Cellular Biochemistry 2008, 105(4):965-970. 10.1002/jcb.21900, 2591066, 18821584.
48. Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, Fukuyama R, Miyazaki T, Kitaura H, Nakamura K, Fujita T, et al. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Developmental Dynamics 2007, 236(7):1876-1890. 10.1002/dvdy.21187, 17497678.
49. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer research 2008, 68(19):7795-7802. 10.1158/0008-5472.CAN-08-1078, 2596479, 18829534.
50. Dalla-Torre CA, Yoshimoto M, Lee CH, Joshua AM, de Toledo SR, Petrilli AS, Andrade JA, Chilton-MacNeill S, Zielenska M, Squire JA. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 2006, 6:237. 10.1186/1471-2407-6-237, 1609181, 17022822.
51. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharff KA, He G, Bi Y, He BC, et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008, 88(12):1264-1277. 10.1038/labinvest.2008.98, 18838962.
52. Lamour V, Detry C, Sanchez C, Henrotin Y, Castronovo V, Bellahcene A. Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem 2007, 282(50):36240-36249. 10.1074/jbc.M705833200, 17956871.
53. Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH, Hogendoorn PC. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. British journal of cancer 2009, 101(12):2064. 10.1038/sj.bjc.6605482, 2795446, 19997114.
54. Berger M, Muraro M, Fagioli F, Ferrari S. Osteosarcoma derived from donor stem cells carrying the Norrie's disease gene. N Engl J Med 2008, 359(23):2502-2504. 10.1056/NEJMc0807172, 19052138.
55. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007, 25(2):371-379. 10.1634/stemcells.2005-0620, 17038675.